AlphAIAlphAI — Financial news for AI agents
MarketBeatMAR 233 min read$EXPO

JPMorgan Chase & Co. Sells 157,457 Shares of Exponent, Inc. $EXPO

JPMorgan Chase & Co. reduced its stake in Exponent, Inc. (NASDAQ:EXPO) by 24.7% in the third quarter, selling over 157,000 shares, though still holding 480,624 shares valued at $33.39 million. While other institutional investors made significant purchases, company insiders, including the CEO and a VP, sold a combined 9,583 shares. Exponent, which analysts rate a "Moderate Buy" with a $92.50 average target, recently beat earnings estimates and increased its quarterly dividend.

Original reporting
MarketBeat · MarketBeat
Published Mar 23, 2026, 9:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 23, 2026, 9:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
JPMorgan Chase & Co. Sells 157,457 Shares of Exponent, Inc. $EXPO — source image
Source · MarketBeat
Decision brief

The 30-second read

$EXPONeutralMed
01

Why it matters

While insider sales and institutional reductions can signal caution, the company's solid earnings and dividend increase suggest underlying strength.

02

Market read

The news has moderate relevance for traders focusing on the financial sector and mid-cap stocks like EXPO.

03

What to watch

Potential macroeconomic factors or upcoming earnings reports could influence stock movement beyond current news.

Relevance 6/10Timing: short-term (next 1-2 weeks)

Background

JPMorgan's sale reduced its stake by 24.7%, possibly reflecting strategic rebalancing or profit-taking.

Company-level read

Ticker impact

$EXPONeutralMedium confidence
Context

The news involves a significant institutional stake reduction and insider sales, which may signal caution or a shift in perception.

Expected impact

Potential short-term decline of 2-4%, with long-term stability if fundamentals hold.

Evidence & confidence

Insider sales and reduction in institutional holdings could indicate caution, but strong earnings and dividend growth support stability.

Market effects

Sector

The financial services sector may experience slight volatility due to institutional trading patterns.

Regional

Limited regional impact; primarily affects U.S.-based financial stocks.

Global

Minimal global relevance; specific to U.S. markets and financial sector.

Counterpoint

What could challenge this read

Insider sales may be routine and not indicative of negative outlook; institutional holdings could be rebalancing without fundamental concerns.

Key entities

  • Financial Institution
    JPMorgan Chase & Co.

    Major institutional investor reducing stake in Exponent, Inc.

  • Company
    Exponent, Inc.

    Engineering and scientific consulting firm, with recent earnings beat and dividend hike.

Read at source← All news

Related articles

AUG 8
$EXPOMedAI 8/10

Exponent (EXPO) Q2 2026 Earnings Call Transcript

Exponent, Inc. (EXPO) reported Q2 2026 net revenues of $148.9 million, up 12% from $132.9 million a year earlier, and net income of $29.4 million, up 11%. Diluted EPS was $0.60. Management raised FY 2026 revenue guidance to 9% to 10% growth and EBITDA margin to 27.8% to 28.1%, and authorized an additional $50 million for share repurchases.

fool.com6 min
AUG 1
$EXPOMedAI 8/10

Exponent Q2 Earnings Call Highlights

Exponent (NASDAQ:EXPO) reported Q2 EBITDA up 16% to $42.7 million, with EBITDA margin at 28.7% of net revenue versus 27.8% a year earlier. Billable hours rose 8% to about 390,000 and utilization increased to 74%. The company repurchased $67.4 million of stock and paid $14.8 million in dividends. It raised 2026 outlook for net revenue growth of 9% to 10%.

yahoo.com6 min
OCT 2
$COINLow

Coinbase (COIN) Chief Accounting Officer Jennifer Jones Announce

Coinbase Global Inc's (COIN) Chief Accounting Officer Jennifer Jones announced her retirement, effective upon a successor's appointment. The company has a P/S ratio of 10.43, above its historical median, and a GF Score of 78/100. Insiders have sold $343.3 million in shares over the past year. Coinbase remains unprofitable with a TTM net margin of -20.6%.

gurufocus.com2 min
OCT 2
$NKEMed

Freedom Broker Upgrades Nike (NKE) to Buy Despite Lowered Price

Freedom Broker upgraded Nike (NKE) to Buy with a lowered price target of $51 from $54, citing valuation appeal despite Q1 sales challenges in Greater China and the Middle East. NKE trades near $33.58, offering a 4.95% dividend yield and a GF Value™ of $72.64, suggesting significant undervaluation. Insider buying and mixed guru activity signal cautious optimism.

gurufocus.com2 min
OCT 2
$BIOAMedAI 8/10

BioAge Labs, Inc. recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily…

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events BioAge Labs, Inc. (the “ Company ”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“ DME ”), an

SEC EDGAR 8-K2 min